To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratiícation of patients with advanced hepatobiliary carcinoma and the clinical utility of agents that could signiícantly impact patient outcomes. Systemic therapies such as ICI-based combination therapies, TKIs, and targeted therapies have signiícantly improved outcomes for patients with hepatobiliary carcinoma. For patients to beneít from systemic therapies, clinicians must be aware of the latest safety and eïcacy data, and emerging data on sequencing of therapies in hepatobiliary carcinoma.
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2025-01-03 06:00:00
- End Date: 2025-01-03 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Incyte Corporation - Amount: 20000.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 37500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest